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ABSTRACT 
The objective of the present work was to formulate and characterize multi-unit floating drug delivery system of Clopidogrel bisulphate to 
increase the bioavailability and sustain the drug release properties up to 8 h with more predictable drug release kinetics that avoids all or 
nothing emptying effect wherefore to improve patient compliance. Clopidogrel bisulphate floating mini-tablets were prepared  by effervescent 
approach with melt granulation and direct compression techniques alone and in combination using Hydroxypropyl methylcellulose (HPMC) 
K100M and Compritol 888 ATO at different concentrations (20%, 30% and 40% w/w) alone and in combination. Sodium bicarbonate at 
concentration 10% w/w was optimized as gas generating floating agent. Evaluations were carried out on physical parameters, floating behavior 
and influence of type of polymer on drug release rate of prepared mini tablet formulations. All the formulations were subject ed to various 
quality control and in-vitro dissolution studies and corresponding dissolution data were fitted to popular release kinetic equations in order to 
evaluate release mechanisms and kinetics. All the Clopidogrel bisulphate floating mini tablet formulations followed zero order kinetics. As per 
Korsmeyer-Peppas equation, the release exponent “n” ranged 0.561-0.758 indicating that drug release from all the formulations was by non-
Fickian diffusion mechanism. Based on the results, Clopidogrel bisulphate floating mini tablets prepared by employing combination of 20% 
w/w HPMC K100M and 20% w/w Compritol 888 ATO offered desired in-vitro floating time and drug dissolution profile. 
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INTRODUCTION 
Oral controlled release drug delivery systems with ability to 
retain in the stomach are called gastro-retentive drug 
delivery system (GRDDS) which are aimed to enhance drug 
therapy with or without targeted action by prolonging the 
gastric residence time after oral administration [1].  
The controlled gastric retention of the formulation may be 
achieved by the various approaches such as floatation, 
mucoadhesion, sedimentation, expansion and modified 
shape systems. Among the various approaches, floating drug 
delivery system (FDDS) is one of the potential approach for 
prolonged gastric retention to improve solubility, reduces 
drug waste thereby improves bioavailability for the drugs 
that are less soluble in a high pH environment. FDDS offer 
the most effective and rational protection against early and 
random gastric emptying compared to the other methods 
proposed for prolonging the gastric residence time of solid 
dosage forms [2]. Most of the floating systems previously 
reported are single unit systems such as tablets and capsules. 
However, the problems such as all or nothing emptying of 
single unit floating dosage forms made them unreliable and 
irreproducible in prolonging the gastric residence time, 
which led to the development of multiple unit floating 
systems [3].  
Multiple unit floating drug delivery systems, such as mini-
tablets with diameter of 3-6mm, show several advantages 
over single unit system, which include avoiding all or nothing 
emptying, more predictable drug release kinetics, less chance 
of localized mucosal damage and administration of units 
with different release profiles or containing incompatible 
substance. Mini tablet have the advantages of both tablets 
and pellets and shows more reliable dissolution profiles than 
single units, which means better bioavailability with more 
and even absorption of the drugs. In addition, they offer 
dosage forms of equal dimensions and weight with smooth 
regular surface that could be obtained in a reproducible and 
continuous way. Like other multiple unit systems, multiple 
mini-tablets can be filled into hard gelatin capsules that 
release these subunits after disintegration [4, 5]. 
Rama Koteswararao et al                                                                                  Journal of Drug Delivery & Therapeutics. 2019; 9(4):173-180 
 
ISSN: 2250-1177                                                                                  [174]                                                                                 CODEN (USA): JDDTAO 
Clopidogrel is a thienopyridine class inhibitor of P2Y12 
adenosine-5-diphosphate (ADP) platelet receptors and used 
to inhibit blood clots in coronary artery disease, peripheral 
vascular disease and cerebrovascular disease. Clopidogrel is 
a pro-drug of carboxyl clopidogrel activated in the liver by 
cytochrome P450 and CYP2C19 enzyme. The active 
metabolite has elimination half-life of about 7-8 h and acts by 
forming a disulfide bridge with the platelet ADP receptor. 
Clopidogrel bisulphate is a BCS class II drug and exhibits pH 
dependent solubility and it is very soluble at pH value < 3. 
Following oral administration, it is well-absorbed with 
bioavailability of about only 50% due to poor water 
solubility. The main side effects of the drug are gastric 
bleeding and clopidogrel drug resistance during chronic 
treatment [6].   
A sustained release floating clopidogrel formulation may be 
desired for a number of reasons, such as improving the 
bioavailability and to minimize the side effects of the drug 
such as gastric bleeding and to prevent the development of 
drug resistance wherefore to improve patient compliance 
[7]. Various single and multiple units of clopidogrel floating 
formulations has been reported in the literature, but very 
little work was carried in the field of multi-unit mini-tablets 
technology. The aim of the present study was to formulate 
and characterize clopidogrel bisulphate multi-unit floating 
mini-tablets to increase the bioavailability and sustain the 
drug release properties up to 8 h with more predictable drug 
release kinetics and avoiding all or nothing emptying effect 
using hydrophilic polymer, HPMC K100M and hydrophobic 
polymer, Compritol 888 ATO. 
MATERIALS AND METHODS 
Materials  
Clopidogrel bisulphate Form-I (gift sample from Dr. Reddy’s 
laboratories, Hyderabad), Compritol ATO 888, HPMC K100M, 
Sodium bicarbonate, Microcrystalline cellulose, Magnesium 
stearate, Talc and all other ingredients are of laboratory 
grade.  
Drug-excipient compatibility studies 
Drug-excipient compatibility studies were performed for 
pure drug and physical mixture of optimized formulation of 
drug with polymers. The physical mixture samples were 
subjected to Fourier Transform infrared (FT-IR) studies. 
Spectra of drug and optimized formulation were taken and 
analyzed for any major interaction due to presence of 
polymers and other ingredients [8]. 
Micromeritic properties 
The pure drug and prepared formulation powder blends 
before compression were evaluated for the angle of repose, 
bulk density (BD), tapped density (TD), Carr’s index(CI) and 
Hausner’s ratio(HR).  
Angle of repose was determined by fixed funnel method by 
placing ten grams of powder blend in a plugged glass funnel 
and was then allowed to flow through the funnel orifice by 
removing the cotton plug from the funnel orifice. The height 
of the heap (h) formed as well as the radius of the heap (r) 
was noted. The angle of repose () was calculated as: Tan   = 
(h/r). 
BD and TD of 10 g of powder blend were determined by 
using 50 ml graduated cylinder. The volume occupied by the 
blend was read and the BD calculated in g/ml. The cylinder 
containing the blend was tapped until constant volume was 
obtained using bulk density apparatus from a height of 2 cm 
and the TD calculated in g/ml. The percentage 
compressibility (CI) was calculated from the difference 
between the TD and the BD divided by the TD and the ratio 
expressed as a percentage. The HR is the ratio between the 
TD and BD [9]. 
Determination of lambda (ʎ) max by Ultra Violet (UV) 
spectroscopy  
The stock solution (1000 µg/ml) of Clopidogrel bisulphate 
was prepared in 0.1N hydrochloric acid (HCl). This solution 
was appropriately diluted with 0.1N HCl to obtain a 
concentration of 10 µg/ ml. The UV spectrum was recorded 
in the range of 200-400 nm on double beam UV-visible 
spectrophotometer. The spectrum and wavelength of 
maximum absorption were recorded. 
Preparation of standard curve 
The stock solution (1000 µg/ml) of Clopidogrel bisulphate 
was prepared in 0.1 N HCl and from this 10 ml of solution 
was taken and the volume was adjusted to 100 ml with 0.1N 
hydrochloric acid (100μg/ml). The above solution was 
suitably diluted with 0.1N hydrochloric acid to get the series 
of dilutions containing 10, 20, 30, 40, 50μg/ml of clopidogrel 
bisulfate solutions. The absorbance of these solutions were 
measured at 270.4 nm against blank i.e. 0.1 N HCl. The 
coefficient of correlation and equation for the line are 
determined [10]. 
Preparation of clopidogrel bisulfate floating mini tablets 
The clopidogrel bisulfate floating mini matrix tablets were 
prepared by effervescent approach with hydrophilic 
polymer, HPMC K100M and hydrophobic polymer, Compritol 
888 ATO at varying concentrations (20%, 30%, 40% w/w) as 
shown in the Table 1 along with all other excipients. Sodium 
bicarbonate at concentration 10% w/w was optimized as gas 
generating floating agent. All the ingredients were passed 
through sieve 44. The formulation F1 to F3 were prepared by 
melt granulation method wherein Compritol 888 ATO was 
melted in a porcelain dish on hot plate and weighed drug 
was added to it. The resultant mixture was allowed to 
solidify at room temperature and passed through sieve 30 to 
form granules for compression. The formulations F4 to F6 
were prepared by direct compression method using HPMC 
K100M. The formulations F7 to F9 were prepared by 
combination of Compritol 888 ATO and HPMC K100M 
wherein melt granulation was employed to incorporate the 
drug into Compritol polymer matrix then followed by direct 
compression method using HPMC K100M. The required 
quantities of other ingredients were added to the blend and 
mixed geometrically. The blend was lubricated with 
magnesium stearate and talc. The final blend was 
compressed into mini tablets using 5 mm size round concave 
single tip punch on multi station rotary compression 
machine. In this work, each dose comprised 10 mini tablets 
which are equivalent to 98 mg clopidogrel bisulphate.
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Table 1: Composition of clopidogrel bisulfate floating mini tablets 
 
Ingredients (mg/tablet) F1 F2 F3 F4 F5 F6 F7 F8 F9 
Clopidogrel Bisulfate 9.8 9.8 9.8 9.8 9.8 9.8 9.8 9.8 9.8 
Sod Bicarbonate  5 5 5 5 5 5 5 5 5 
Compritol ATO 888 10 15 20 0 0 0 5 7.5 10 
HPMC K100M 0 0 0 10 15 20 5 7.5 10 
Aerosil  0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Magnesium stearate 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Microcrystalline cellulose 24.2 19.2 14.2 24.2 19.2 14.2 24.2 19.2 14.2 
 Total weight 50 50 50 50 50 50 50 50 50 
 
Evaluation of physical parameters of floating mini 
matrix tablets [11] 
Tablet weight uniformity:  
A total of 20 mini tablets were weighed individually, average 
weight was calculated and the individual tablet weights were 
compared with the average weight. The tablets will meet the 
USP test if not more than two tablets are outside the 
percentage limit (± 10%) and if no tablets differ by more 
than two times the percentage limit. 
Thickness test: 
The thickness of three randomly selected mini-tablets from 
each formulation was measured with a Vernier calliper scale 
and their thickness was recorded and the average thickness 
along with the standard deviation is reported. 
Hardness test:  
Hardness of the tablet is the force applied across the 
diameter of the tablet to break the tablet. The hardness of 10 
tablets was determined using Monsanto hardness tester and 
the average is calculated and reported with the standard 
deviation and expressed in kg/cm2.  
Friability test: 
The friability of tablets was determined using Roche 
friabilator. Six mini tablets (6) were initially weighed (W0) 
and transferred into friabilator. The friabilator was operated 
at 25 rpm for 4 min or run up to 100 revolutions. The tablets 
were weighed again (W). The % friability was then 
calculated by the following equation. 
%F = (1−W/W0) × 100 
% Friability of tablets <1% are considered as acceptable. 
Drug content: 
A total of 30 mini tablets were weighed and powdered. The 
quantity of powder equivalent to 98 mg of clopidogrel 
bisulfate was dissolved in 100 ml of 0.1 N HCl. Then the 
solution was filtered, diluted suitably and analyzed using an 
UV-visible spectrophotometer at 270.4 nm. 
In-vitro buoyancy studies 
The in-vitro buoyancy was determined using the USP 
dissolution apparatus II at 50 rpm containing 900 ml of 0.1 N 
HCl as the dissolution medium was maintained at 37 ± 0.5 ℃. 
Ten mini-tablets were dropped in a basket and the time 
required for the tablet to rise to the surface and float was 
determined as floating lag time (FLT) and the duration of the 
time the tablet constantly floats on the dissolution medium 
was noted as the total floating time respectively. 
In vitro drug release studies  
The in-vitro drug release study was performed for all the 
formulations using USP Type II dissolution apparatus at 50 
rpm for 8 hours. Ten mini-tablets equivalent to 98 mg of 
clopidogrel bisulphate were placed in 900 ml of dissolution 
medium i.e. 0.1 N HCl maintained at 37± 0.5℃. Aliquots of 5 
ml were withdrawn at specified intervals of time, filtered and 
replenished with 5 ml fresh dissolution medium. Sample’s 
absorbance was measured at ʎmax 270.4 nm using UV-
visible spectrophotometer. The studies were performed in 
triplicate. The cumulative percentage drug released was 
calculated at each time interval using slope obtained from 
the standard curve. 
Kinetic modeling of drug release [12]: The data obtained 
from in vitro drug release studies were fitted to the following 
kinetic equations: 
Zero order release kinetics equation: Qt = Q0+ K0t; Where Qt 
is the amount of drug dissolved in time t, Q0 is the initial 
amount of drug in the solution (most times, Q0 = 0) and K0 is 
the zero order release constant expressed in units of 
concentration/time and graph was plotted for cumulative 
amount of drug released vs. time.   
First order release kinetics equation: Log C = log 
C0−Kt/2.303; where C0 is the initial concentration of drug, K 
is the first order rate constant and t is the time and graph 
was plotted for log cumulative percentage of drug remaining 
vs. time. 
Higuchi equation defines a linear dependence of the active 
fraction released per unit of surface (Q) on the square root of 
time and can be expressed as Q = KH t1/2; Where, KH is the 
release rate constant. This equation describes drug release 
as a diffusion process based on the Fick’s law, square root 
time dependent. 
In order to define a model, which would represent a better fit 
for the formulation, dissolution data were further analyzed 
by Peppas and Korsmeyer equation: Mt/M∞ = Ktn; Where 
Mt/M∞ is a fraction of drug released at time t, K is the 
release rate constant and n is the release exponent. In this 
model, the value of n characterizes the release mechanism of 
drug. For the case of cylindrical tablets, n = 0.45 corresponds 
to a Fickian diffusion mechanism, 0.45 < n < 0.89 to non-
Fickian transport, n = 0.89 to Case II (relaxation) transport, 
and n > 0.89 to super Case II transport. 
RESULTS AND DISCUSSION 
Calibration curve of clopidogrel bisulphate 
An UV spectro-photometric method was used for estimation 
of clopidogrel bisulphate. A solution of clopidogrel 
bisulphate (10μg/mL) was scanned in the wavelength range 
of 200-400 nm and found to have maximum absorption 
(λmax) at 270.4 nm (Fig. 1). The standard plot of clopidogrel 
bisulphate was prepared in 0.1 N HCl (pH 1.2) and showed 
good linearity with R2 value of 0.9999 (Fig. 2). 
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Fig. 1: UV scan spectrum curve of clopidogrel bisulfate 
 
Fig. 2: Calibration curve of clopidogrel bisulfate at 270.4 
nm
 
Drug-excipient compatibility studies  
The FT-IR spectrum of pure drug was compared with 
optimized formulation. The characteristic peaks which are 
observed for the pure drug in the FTIR spectra (Fig. 3a) were 
also observed for optimized formulation (Fig. 3b) with little 
shifting of peaks suggesting that there is no interaction 
between drug and excipients (Table 2). 
 
Table 2: Functional groups and range for Clopidogrel bisulphate and optimized formulation 
Functional groups Clopidogrel bisulphate (Form I) Optimized formulation (F9) 
O-H Carboxylic 3450.10 3440.27 
C-H Stretching 2917.69 2917.31 
C=O Stretching 1750.42 1737.54 
C-O Stretching 1129.12 1110.24 
Form I unique band 839.04 839.04 
 
 
 
Fig. 3a: FT-IR spectra of pure clopidogrel bisulphate 
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Fig.  3b: FT-IR spectra of physical mixture of clopidogrel bisulphate formulation F9 blend with HPMC K100M and 
Compritol 888 ATO. 
Micromeritic properties 
The micromeritic properties of pure drug of clopidogrel 
bisulfate showed good flow properties as per observed 
values of CI (11.11) and angle of repose (26.10). The flow 
properties of the formulation powder blends were also 
showed fair flow properties as per observed values of CI and 
angle of repose. The micromeritic properties of pure drug 
and optimized batch of the formulation were shown in Table 
3.
 
Table 3: Micromeritic properties of drug and optimized batch of clopidogrl blend 
Parameters Pure drug F9 
Angle of repose 26.10 30.54 
Carr’s index (%) 11.11 17.78 
Hausner’s ratio 1.12 1.21 
 
Evaluation of physical parameters of floating mini 
tablets 
All the prepared formulations were tested for various 
physical parameters such as thickness, weight variation, 
hardness and friability. Results of the physical tests were 
shown in Table 4. The hardness of all the formulations was 
found to be in the range of 4-5 kg/cm2. The friability of all 
the formulations was found to be <1%. The drug content of 
the formulations was in between 98% and 102%. Hence, all 
the clopidogrel floating mini tablet formulations were of 
good quality and fulfilled the official pharmacopoeial 
specifications with regard to drug content, hardness and 
friability.
 
Table 4: Physical characteristics of clopidogrel floating mini tablet formulations 
Formulation 
code 
Thickness(mm)-
(n=3) 
Weight Variation 
(n=20) 
Hardness (kg/cm2) 
(n=10) 
Friability 
(%) 
(n=6) 
Assay (%) 
(n=3) 
F1 2.62±0.02 50.29±1.10 4.16±0.06 0.12 101.21±0.88 
F2 2.61±0.01 48.11±1.11 4.25±0.02 0.15 100.01±0.90 
F3 2.61±0.02 49.84±1.15 4.18±0.07 0.17 99.95±1.17 
F4 2.62±0.02 50.87±1.12 4.23±0.01 0.15 102.98±1.05 
F5 2.64±0.03 50.22±1.10 4.20±0.08 0.16 99.23±1.23 
F6 2.65±0.02 51.12±1.06 4.15±0.03 0.18 100.20±0.96 
F7 2.62±0.02 48.99±1.15 4.17±0.02 0.19 101.12±1.20 
F8 2.62±0.01 50.28±1.12 4.11±0.05 0.16 98.89±1.02 
F9 2.63±0.02 48.99±1.15 4.16±0.09 0.18 99.98±1.22 
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Floating properties of clopidogrel floating mini matrix 
tablets    
All the formulations were tested for floating properties such 
as floating lag and total floating time. The results of in-vitro 
buoyancy study are shown in the Table 5. Sodium 
bicarbonate was used as gas generating agent at 10% w/w 
concentration. The sodium bicarbonate induces CO2 
generation in the presence of acidic dissolution medium (0.1 
N HCl). The gas generated is trapped and protected within 
the gel formed by hydration of the polymer, thus decreasing 
the density of the tablet below 1 gm/ml, and the tablet 
becomes buoyant. Mini tablet formulations prepared with 
Compritol 888 ATO (F1 to F3) did not show floating 
behaviour because the formulations did not swell and hence 
failed to form a gel and the CO2 generated did not get 
entrapped, thus these formulations failed to float the tablet. 
The total floating time of other formulations (F4 to F9) was 
observed in between 10 to 12 h with floating lag time <1 min 
and showed better and desired floating characteristics. 
Pictorial presentation of in-vitro buoyancy study results of 
optimized formulation (F9) was shown in Figure 4. 
 
Table 5: In-vitro buoyancy data of clopidogrel floating minitablets 
Formulation code Floating Lag Time* (Seconds) (n=10) Floating time (Hours)* 
F1 NF NF 
F2 NF NF 
F3 NF NF 
F4 17±2.48 10 
F5 18.±1.75 >12 
F6 18±2.36 >12 
F7 23±1.84 10 
F8 24±1.84 >12 
F9 24±.2.38 >12 
*NF- Not Floated 
 
 
Fig. 4: Pictorial presentation of in-vitro buoyancy study of optimized formulation (F9) 
 
In-vitro drug release studies  
The release of clopidogrel bisulphate from all the mini tablet 
formulation was found to be slow and sustained. The in-vitro 
drug release profiles of the formulations prepared with 
hydrophobic polymer, Compritol are shown in Figure 5a. The 
drug release extended from 4-8 h and the 1 h initial drug 
release was varied between 21% and 49%. F1 formulation 
released more than 90% of drug within 4 h whereas 
formulation F2 and F3 showed 98% and 96% drug released 
in 7 and 8 h respectively. However, these formulations did 
not show any floating characteristics as the tablet 
formulations did not swell. 
 
 
Fig. 5a: Cumulative percentage drug release of 
formulations with Compritol 888 ATO
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Fig. 5b: Cumulative percentage drug release of 
formulations with HPMC K100M 
 
Fig. 5c: Cumulative percentage drug release of 
formulations with combination of Compritol 888 ATO 
and HPMC K100M 
The in-vitro drug release profiles of the formulations 
prepared with hydrophilic polymer, HPMC are shown in 
Figure 5b. The 1 h initial drug release was varied between 
17-36%. F4 and F5 formulations released more than 90% of 
drug within 5 h and 7 h respectively whereas the drug 
release from F6 formulation was slow and failed to release 
the complete drug at 8 h. It shows that the increase of HPMC 
content affects significantly the matrix tablet release 
behaviour. The formulations prepared with hydrophilic 
polymer HPMC showed greater drug release retardation 
than the hydrophobic polymer Compritol formulations at 
their defined respective concentrations as more than 96% 
drug was released in 8 h from matrix tablets containing 30% 
compritol but matrix tablets containing 30% HPMC only 
released 85 % drug at the same time. 
The in-vitro drug release profiles of the formulations 
prepared with combination of Compritol and HPMC are 
shown in Figure 5c. The 1 h initial drug release was varied 
between 18-40%. F7 and F8 formulations released almost 
90% of drug within 4 h and 6 h respectively. F9 formulation 
released more than 90% of drug within 8 h and showed 
better and desired drug release profile, hence it was 
considered as an optimized formulation. Incorporation of 
compritol with HPMC increases drug release from the 
formulation. This may be attributed to increased penetration 
of the solvent molecules in presence of the hydrophobic 
polymer, leading to enhance drug diffusion from the matrix. 
Formulations F1, F4 and F7 showed rapid/bust drug release 
almost 35-50% in 1 h which may be due to insufficient 
polymer concentration.  
Kinetic modeling of drug release 
Analysis of the drug release data as per zero order and first 
order kinetic models indicated that all the formulations 
followed zero order kinetics and dissolution rate constant 
(K) values were presented in Table 6. Higuchi plots were 
found to be linear with “r2” > 0.9633 in all the clopidogrel 
floating mini tablets. In the analysis of release data as per 
Korsmeyer-Peppas equation, the release exponent “n” was in 
the range 0.561-0.758 indicating non-fickian diffusion as the 
release mechanism from all the clopidogrel floating 
minitablets. The drug release rate of clopidogrel was found 
to be affected by the type and concentration of the polymer 
used in the formulation. As the concentration of the polymer 
was increased, the drug release was found to be retarded.
 
Table 6: Regression coefficient (R2) values of floating minitablet formulations for different kinetic models 
Formulation code 
 
R2 
Peppas (n) Zero order rate constant (K) 
Zero 
First 
 
Higuchi 
 
Korsmeyer–Peppas 
 
F1 0.9354 0.8294 0.9841 0.9480 0.758 22.98 
F2 0.9678 0.8721 0.9869 0.9914 0.587 13.40 
F3 0.9932 0.8111 0.9633 0.9888 0.634 11.39 
F4 0.9710 0.7887 0.9758 0.9864 0.576 17.89 
F5 0.9758 0.8283 0.9828 0.9994 0.623 11.95 
F6 0.9882 0.8934 0.9645 0.9917 0.667 9.75 
F7 0.9558 0.8621 0.9903 0.9954 0.561 18.37 
F8 0.9794 0.6268 0.9785 0.9957 0.632 13.19 
F9 0.9935 0.8702 0.9674 0.9874 0.637 10.65 
 
CONCLUSION 
In this research work, an attempt has been made to develop 
multi-unit floating mini-tablets of clopidogrel bisulphate by 
effervescent approach using the polymers HPMC K100M and 
Compritol 888 ATO to sustain the drug release properties up 
to 8 h with more predictable drug release kinetics avoiding 
all or nothing emptying effect in order to improve 
bioavailability and to minimize the side effects of the drug 
such as gastric bleeding and to prevent the development of 
drug resistance. According to the above results, optimised 
floating mini-tablet formulation (F9) prepared by employing 
combination of 20% w/w HPMC K100M and 20% w/w 
Compritol 888 ATO with 10% w/w sodium bicarbonate 
offered desired in-vitro floating time and drug dissolution 
profile and the adopted method yielded uniform and 
reproducible floating mini matrix tablets. Thus all the major 
objectives of this investigation were fulfilled. 
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